0000950170-23-071114.txt : 20231218 0000950170-23-071114.hdr.sgml : 20231218 20231218163013 ACCESSION NUMBER: 0000950170-23-071114 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231214 FILED AS OF DATE: 20231218 DATE AS OF CHANGE: 20231218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Loew Caroline CENTRAL INDEX KEY: 0001989488 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41837 FILM NUMBER: 231494153 MAIL ADDRESS: STREET 1: MURAL ONCOLOGY LTD. STREET 2: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mural Oncology plc CENTRAL INDEX KEY: 0001971543 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 BUSINESS PHONE: 353 1 905 8020 MAIL ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 FORMER COMPANY: FORMER CONFORMED NAME: Mural Oncology Ltd DATE OF NAME CHANGE: 20230403 FORMER COMPANY: FORMER CONFORMED NAME: Pistachiovale Ltd DATE OF NAME CHANGE: 20230329 4 1 ownership.xml 4 X0508 4 2023-12-14 0001971543 Mural Oncology plc MURA 0001989488 Loew Caroline C/O MURAL ONCOLOGY PLC 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 IRELAND true true false false Chief Executive Officer false Ordinary Shares 2023-12-14 4 A false 167276 0.00 A 167276 D Ordinary Shares 2023-12-14 4 A false 37171 0.00 A 37171 D Stock Option (right to buy) 3.61 2023-12-14 4 A false 379690 A 2033-07-02 Ordinary Shares 379690 379690 D Represents a restricted stock unit award originally granted by Alkermes plc ("Alkermes") that was converted into a restricted stock unit ("RSU") award of Mural Oncology plc (the "Issuer") in connection with the spin-off of the Issuer from Alkermes (the "Spin-off"). Consists of ordinary shares issuable under 167,276 RSUs. Each RSU represents the right to receive one ordinary share of the Issuer upon vesting. These RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer. Consists of ordinary shares issuable under 37,171 RSUs. Each RSU represents the right to receive one ordinary share of the Issuer upon vesting. These RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of December 14, 2023, subject to the reporting person's continued service with the Issuer. Represents an option award originally granted by Alkermes that was converted into an option award of the Issuer in connection with the Spin-off. This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer. /s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew 2023-12-18